Sample preparation for FACS analysis: Whole blood samples were collected from the portal vein of anaesthetized mice (n = 6-10 per group) using a heparin-coated syringe (Sarstedt, Helsingborg, Sweden) and transferred to EDTA-coated collection tubes (Sarstedt, Helsingborg, Sweden). For plasma extraction, samples were centrifuged for 20 min (5000 rpm, 4 °C) and the supernatant was used in mass spectrometry. For fluorescence activated cell sorting (FACS) analysis, whole blood samples from EDTA collection tubes were directly processed using a standardized red blood cell (RBCs) lysis protocol. Briefly, RBCs were lysed protected from light in freshly prepared 1X RBC lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 10 min at room temperature. To stop the reaction, an equal amount of 1× PBS was added before centrifuging the samples at 300× g at room temperature. The resulting cell pellet was washed and re-suspended in the appropriate FACS buffer (PBS, 2 mM EDTA, 2% FBS) containing Fc-Block (1/200; Clone 2.4G2; BD Pharmingen) for further cell surface staining. 30 min of antibody incubation was conducted at 4 °C under the protection from light. Antibodies used for cell staining are listed in Table A1 .
. Antibodies utilized in flow cytometry experiments for whole blood and brain tissue. Mass spectrometric measurement of S1P concentrations: The two hemispheres of the brain from half the animals per group were separated and distributed to either mRNA-protein extraction or mass spectrometry. For the isolation of the lipid fraction and mass spectrometric determination of S1P levels, plasma samples (n = 6-8) were diluted in 1ml extraction buffer (Isopropanol:water:ethyl acetate (7:1:12) and 30 µM (IS; D-erythro-sphingosine-1-phosphate) as internal standard (IS), mixed and centrifuged at 5000 rpm for 3 min. The collected supernatant was directly used for mass spectrometry.
Antigen
Samples were analysed by LC-MS/MS on an API 3000 (AB Sciex) triple quadrupole mass spectrometer integrated on an Acquity UPLC system (Waters Corporation, Milford, MA, USA). A Kinetex (Phenomenex, Torrance, CA, USA) 2.6 µm XB C18 100 Å 50 × 2.00 mm column was used as stationary phase. The column temperature was set at 60 °C. The Mobile phases consisted of (A) 75% methanol, 0.1% formic acid and 5 mM ammonium formate and (B) 100% methanol, 0.1% formic acid and 5 mM ammonium formate. The gradient elution profile was as follows: 0 min 100% A, from 0 min to 2 min the % A decreased from 100% to 0 % and was kept at 0% until 5.5 min, when it was returned to initial conditions at 5.6 min until 6 min. Flow was set at 0.6 mL/min. Analyte was detected in positive electrospray ionization (ESI) mode. The ion spray voltage was set at 5000 Volts and source temperature at 400 °C. Data was acquired in multiple reaction monitoring (MRM) mode. Transitions selected were 380.1/264.4 for S1P and 387.3/271.5 for the internal standard. Results were integrated and calculated using linear regression by the Analyst 1.4.2 software (AB Sciex).
Quantitative real-time PCR (qRT-PCR): The two hemispheres of the brain from half the animals per group were separated and distributed to either mRNA-protein extraction or mass spectrometry. RNA was isolated from brain tissue (n = 4-8 per group) using a Trizol ® method according to the manufacturer's protocol. As per instructions using a "High Capacity Reverse Transcriptase Kit" kit (Applied Biosystems, Göteborg, Sweden), 1 µg of total RNA was reverse transcribed with random hexamer primers. The resulting cDNA was diluted to a final volume of 500 µL and subsequently used as a template for qRT-PCR reactions. qRT-PCR was performed in triplicates using Power SYBR ® Green PCR Master Mix (Applied Biosystems, Göteborg, Sweden) according to the manufacturer's instructions. Each reaction comprised 1ng cDNA, 3ul master mix and 0.2 uM final concentration of each primer. Cycling and detection were carried out using a CFX Connect™ Real-Time PCR Detection System and data quantified using Sequence CFX Manager™ Software (Biorad, Göteborg, Sweden). qRT-PCR was performed for a total of 40 cycles (95 °C 15 s, 60 °C 60 s) followed by a dissociation stage. All primers (see Table A2 for primer sequences) were optimized prior first usage by assessing the optimal annealing temperature using a temperature gradient. Specificity was monitored using melt-curve validation. The efficiency, reproducibility and dynamic range of a qPCR assay were determined by constructing a standard curve using serial dilutions of pooled cDNA representative of each sample to be analysed and water as negative control. A standard curve was constructed by plotting the log of the dilution factor against the CT value obtained during amplification of each dilution (performed in duplicates). The qPCR assay was considered optimal with a coefficient of determination (R 2 ) value >0.950 and similar CT values of the replicates. All data were normalized to L14 and quantification was carried out via the absolute method using standard curves. Test samples were assayed with the standards in the same experimental run. The standard curve constructed from the diluted standard template was used to determine the target quantity in the samples by interpolation. Table S2 . Primer sequences used in qPCR experiments.
Target
Forward primer Reverse primer Tm
Western Blotting: Protein isolation was performed in a sequential precipitation of RNA, DNA and protein from a single sample using the Trizol ® method. Following RNA and DNA precipitation, protein was extracted from the phenol-ethanol supernatant by isopropanol precipitation according to the manufacturer's instructions. After removal of impurities and solubilization, protein concentration was determined by PIERCE BCA protein assay (Fisher Scientific, Göteborg, Sweden). Western blotting was carried out according to standard protocols. Briefly, samples were heated for 10 min at 95 °C in sample buffer (2.0 mL 1M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% 14.7 M β-mercaptoethanol 12.5 mM EDTA, 0.02% bromophenol blue). Proteins were then separated on 12-15% Bis-acrylamid mini gels containing 0.1% 2,2,2-Trichloroethanol for subsequent visualization of protein loading using a Chemidoc MP imaging system (Biorad, Stockholm, Sweden). Following protein transfer onto PVDF membranes (Biorad, Stockholm, Sweden), transfer efficiency was checked using a Chemidoc MP imaging system. The membranes were blocked for 60 min in 1% bovine serum albumin (in phosphate-buffered saline containing 1% Tween 20 (PBST); 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM K2HPO4; pH 7.4) and sequentially incubated with the primary and secondary antibodies. A 1:1000 dilution for the primary antibody (CD3 and SphK1 (Abcam, Cambridge, UK), β-tubulin (Sigma Aldrich, Stockholm, Sweden)) and 1:10,000 for the HRP-labelled secondary antibody (anti-rabbit IgG or anti-mouse IgG BioNordica, Stockholm, Sweden) were utilized. All antibodies were diluted in 1% bovine serum albumin in PBST. A standard chemiluminescence procedure was used to visualize protein binding in a Chemidoc MP imaging system. The images were evaluated densitometrically using Image Lab 6.0.1 (Biorad, Stockholm, Sweden) or "Image J" software (1.48v, http://imagej.nih.gov/ij). control AngII FTY720 * whole brain tissue from normotensive and hypertensive WT mice treated with FTY720 for two constitutive weeks. Data expressed as mean ± SEM; n = 4 per group * p < 0.05 after single unpaired comparisons. Figure S6 . FTY720 does not affect the concentration difference between brain and plasma S1P levels (delta S1P) in hypertensive WT mice. Calculation of the difference between the S1P concentration in brain and plasma samples obtained by mass spectrometry from hypertensive WT mice treated with 1mg/kg BW FTY720 or placebo-treated hypertensive mice. Data expressed as mean ± SEM; n = 6-7 per group. Table S4 . Circulating CD3+ T-cells in WT mice, SphK1 −/− mice and WT mice treated with FTY720. FACS-based assessment of circulating CD45+ CD3+ cells in whole blood isolated from saline and AngII-treated SphK1 −/− mice as well as normotensive and hypertensive WT mice subjected to twoweeks administration of FTY720. Data expressed as mean ± SEM; n = 6; p values calculated for single unpaired comparisons. Table S6 . Gender-specific distribution of S1P concentrations in plasma and brain. Mass spectrometrybased assessment of S1P concentrations in plasma and brain tissue of all experimental groups separated according to gender. Data expressed as mean ± SEM.
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